KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Common Equity (2016 - 2025)

Thermo Fisher Scientific's Common Equity history spans 17 years, with the latest figure at $53.4 billion for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 7.71% year-over-year to $53.4 billion, compared with a TTM value of $53.4 billion through Dec 2025, up 7.71%, and an annual FY2025 reading of $53.4 billion, up 7.71% over the prior year.
  • Common Equity for Q4 2025 was $53.4 billion at Thermo Fisher Scientific, up from $51.0 billion in the prior quarter.
  • The five-year high for Common Equity was $53.4 billion in Q4 2025, with the low at $35.1 billion in Q2 2021.
  • Average Common Equity over 5 years is $44.8 billion, with a median of $44.7 billion recorded in 2022.
  • Year-over-year, Common Equity rose 23.52% in 2021 and then rose 3.15% in 2023.
  • Tracing TMO's Common Equity over 5 years: stood at $40.9 billion in 2021, then rose by 7.78% to $44.0 billion in 2022, then rose by 6.11% to $46.7 billion in 2023, then rose by 6.12% to $49.6 billion in 2024, then increased by 7.71% to $53.4 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's Common Equity are $53.4 billion (Q4 2025), $51.0 billion (Q3 2025), and $50.5 billion (Q2 2025).